Status:
COMPLETED
Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate relative bioavailability during the new and traditional formulations of SHR6390 in healthy subjects
Eligibility Criteria
Inclusion
- Execute an informed consent;
- Male or female aged 18-45 years (including threshold) on the date of signing the informed consent;
- Male body weight ≥ 50 kg, female body weight ≥ 45 kg, body mass index (BMI) in the range of 19.0-26.0 kg / m2 (including the critical value);
- Physical examination, vital signs, laboratory examination , 12-Lead ECG, abdominal B-ultrasound, chest X-ray, etc. are normal or abnormal, but the researcher has no clinical significance according to NCI CTCAE 5.0 standard;
- Fertile subjects had no family planning and had to take acceptable contraceptive measures and no plans to donate eggs and sperm within 7 months from the date of signing informed consent to the last medication; the serum pregnancy test of fertile women within 72 hours before the first administration of the study drug should be negative.
Exclusion
- Those who have previously suffered from primary diseases of important organs, including but not limited to neuropsychiatric, cardiovascular, digestive tract, respiratory system, urinary, endocrine, blood, immune and other diseases, which are judged by the researchers to be unsuitable for the trial;
- Patients who have received any previous operation affecting gastrointestinal absorption;
- Patients who had received any surgery within 6 months before screening, or planned to undergo surgery during the study period;
- Those who lost blood or donated more than 400 ml or received blood transfusion within 3 months before screening;
- HBsAg positive, HCV antibody positive, HIV antibody positive, syphilis antibody positive;
- History of drug use or drug abuse, or drug screening positive;
- Smoking and alcohol addict and unable to stop smoking during the test period; those with positive alcohol screening; those with positive nicotine screening;
- Allergic constitution, including severe drug allergy or drug allergy history; known allergy to shr6390 tablets or its excipients;
- Having swallowing resistance or disorder, affecting drug absorption;
- Participated in other clinical trials and taken the study drug within 3 months before taking the study drug for the first time;
- Inducers or inhibitors of CYP3A4, CYP2C9 and CYP2C8 were taken within 4 weeks before the first administration of study drug;
- Taking any prescription drug, over-the-counter drug, traditional Chinese medicine or food supplement within 2 weeks before taking the study drug for the first time;
- Ingestion of grapefruit containing products, fruit juice, food or beverage containing methylxanthine or alcohol within 72 hours before taking the study drug for the first time; taking strenuous exercise; or having other factors affecting the absorption, distribution, metabolism and excretion of drugs;
- Lactating women;
- The researchers considered that the subjects had any other factors that were not suitable for the trial.
Key Trial Info
Start Date :
December 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 29 2021
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04667156
Start Date
December 13 2020
End Date
January 29 2021
Last Update
October 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 470071